Posledná aktualizácia :
19/11/2024
Infostab
Zoznam zlúčenín
Sumárne zoznamy
Vyhľadávanie kompatibilít
Tabuľka kompatibilít pre inf. spojku Y
Odkazy na literatúru
výskumné tímy
valistab
Poster
Pripojenie
sponzori
Autori
Príručka používateľa
Newsletter
výskumné tímy - Quality Evaluation Team, Samsung Bioepis Co
Quality Evaluation Team, Samsung Bioepis Co
Incheon
sujin8171.park@samsung.com
Odkazy na literatúru
(4)
1
In‑Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period.
Tak M, Jeong H, Yun J, Kim J, Kim S, Lee Y, Park S-J. (sujin8171.park@samsung.com)
Drugs R D -
2023
- ;23,4:363 - 375
2
Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
Park D, Kim J, Yun J, Park S.J. (sujin8171.park@samsung.com)
Adv Ther -
2020
- ; 37: 4308–4324.
3
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Yun J, Kim J, Chung J, Hwang S-J, Park S-J. (sujin8171.park@samsung.com)
Adv Ther -
2019
-
4
Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature.
Park D, Yun J, Hwang S-J, Park SJ. (sujin8171.park@samsung.com)
Adv Ther -
2019
- 36:442–450
Skúmané zlúčeniny
(4)
Adalimumab
Bevacizumab
Eculizumab
Trastuzumab
Mentions Légales
